Open AccessLower Risk of Cardiovascular Events in Postmenopausal Women Taking Oral Estradiol Compared With Oral Conjugated Equine Estrogens
Author(s) -
Nicholas L. Smith,
Marc Blondon,
Kerri L. Wiggins,
Laura B. Harrington,
Astrid van Hylckama Vlieg,
James S. Floyd,
Melody Hwang,
Joshua C. Bis,
Barbara McKnight,
Kenneth Rice,
Thomas Lumley,
Frits R. Rosendaal,
Susan R. Heckbert,
Bruce M. Psaty
Publication year - 2013
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2013.11074
Subject(s) - medicine , odds ratio , hormone therapy , myocardial infarction , stroke (engine) , estrogen , venous thrombosis , population , thrombosis , endocrinology , breast cancer , cancer , mechanical engineering , environmental health , engineering
Little is known about the comparative cardiovascular safety of oral hormone therapy products, which impedes women from making informed safety decisions about hormone therapy to treat menopausal symptoms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom